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Myriam Lavoie, Colin P. Sharp, 
Jacques Pépin, Christopher Pennington, 
Yacouba Foupouapouognigni, Oliver G. Pybus, 
Richard Njouom, and Peter Simmonds
In a post hoc analysis of samples collected in 2009, we 
determined seroprevalence of parvovirus 4 (PARV4) among 
elderly Cameroonians. PARV4 seropositivity was associated 
with receipt of intravenous antimalarial drugs, intramuscular 
streptomycin, or an intramuscular contraceptive, but not 
hepatitis C virus seropositivity. Findings suggest parenteral 
acquisition of some PARV4 infections.
Human parvovirus 4 (PARV4), also known as partetravirus, was identifi ed in 2005 from the plasma 
of an intravenous drug user (IDU) (1). In separate studies 
that used PCR, PARV4 was subsequently documented in 
autopsy tissues from IDUs and persons with hemophilia; in 
bone marrow aspirates from patients with AIDS; and in the 
blood of transplant recipients, hemodialysis patients, and 
infants in Ghana (2–5).
In 2007, 199 (32.4%) of 626 adults tested in Burkina 
Faso, Democratic Republic of the Congo, and Cameroon 
were seropositive by fi rst-generation serologic assay for 
PARV4 (6). In South Africa, prevalence was 36% among 
HIV-infected blood donors but only 4% among their HIV-
seronegative counterparts (6). Although PARV4 presence 
in IDUs and hemophilia patients suggests parenteral 
transmission (7,8), this route has not yet been studied and 
other modes of transmission have not been ruled out. The 
pathogenicity of PARV4 remains unclear, but PARV4 
DNA recently was found in the cerebrospinal fl uid of 2 
children from India who had unexplained encephalitis (9).
During 2010, to investigate the epidemiology of PARV4 
in Africa, we tested for PARV4 antibodies in serum samples 
collected during a 2009 study of a defi ned population of 
elderly Cameroonians among whom prevalence of hepatitis 
C virus (HCV) infection was high. Previous exposures to 
parenteral and sexual risk factors had been documented for 
this population (10–12), indicating that this population had 
been excessively exposed to improperly sterilized syringes 
and needles and that the main risk factor for HCV was the 
administration of intravenous antimalarial drugs, mostly 
before 1960.
The Study
The ethics committees of the Cameroonian Ministry 
of Health and the Centre Hospitalier Universitaire de 
Sherbrooke (Sherbrooke, Quebec, Canada) approved the 
2009 study and 2010 follow-up specimen testing. The 
study was conducted in Ebolowa, southern Cameroon 
(10). Inclusion criteria were age >60 years and consent. 
Exclusion criteria were dementia or inability to 
communicate. With cooperation from community leaders, 
we visited a convenience sample of houses to identify 
participants. We obtained venous samples from participants 
and gathered sociodemographic data and information 
about past intravenous treatment for any disease, past 
parenteral treatment for infectious diseases, transfusions, 
scarifi cations, and circumcision. Vaccine scars were 
documented.
We performed PARV4 IgG detection on each sample 
in replicate by indirect ELISA by using baculovirus-
expressed viral protein 2 and control antigens (8); arbitrary 
unit (AU) values were calculated relative to a control 
sample. Because of a high background reactivity observed 
for this cohort, we additionally stipulated that for positive 
samples, the optical density ratio (ODR) of viral protein 2 
to control must be >1.2; ODRs below this threshold were 
considered negative.
Serologic assays for HCV and treponemal antibodies 
were described in the original study by Pepin et al. (10). We 
detected antibodies against hepatitis B core antigen (HBcAg) 
by using AxSYM (Abbott, Montreal, Quebec, Canada) and 
analyzed data by using Stata 10.0 (StataCorp LP, College 
Station, TX, USA). Proportions were compared by using 
either the χ2 or Fisher exact test. Variables associated with 
PARV4 seropositivity in univariate analysis were tested in 
logistic regression models through nonautomated forward 
selection, continuing until no other variable reached 
signifi cance. Each variable was then eliminated to assess its 
effect by using likelihood ratio tests. We retained in the fi nal 
model variables that enhanced the fi t at the p<0.05 level.
The study comprised 451 persons 60–102 years of age 
(median 70 years); 56% were HCV seropositive, 74% had 
antibodies against Treponema (10), and 95% were anti-
HBcAg seropositive. Seventy-nine (17.5%) persons carried 
PARV4 antibodies.
PARV4 antibodies were more prevalent among persons 
60–64 years of age than among older persons (Table 1). 
Prevalence did not vary by sex or by presence of anti-HCV, 
anti-HBcAg, or treponemal antibodies. The prevalence 
of anti-PARV4 increased, but not signifi cantly, with 
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exposure to intravenous treatments in general. Receipt of 
intravenous antimalarial drugs was associated with PARV4 
seropositivity, which was also more frequent among persons 
treated for tuberculosis and among the few women who 
had received injections of the contraceptive Depo-Provera 
(Pharmacia & Upjohn Company, New York, NY, USA). 
PARV4 seropositivity was not associated with treatments 
delivered by injection against yaws, syphilis, leprosy, or 
trypanosomiasis (data not shown) or with sexually transmitted 
infections. PARV4 seropositivity was less common among 
persons who had a vaccine scar on the left arm.
In multivariate analysis (Table 2), PARV4 
seropositivity was associated with younger age, intravenous 
receipt of antimalarial drugs, and parenteral receipt of 
antituberculosis treatment (the latter was of borderline 
signifi cance) and was less common among persons with 
a left-sided vaccine scar. In that model, Depo-Provera 
injections were associated with PARV-4 seropositivity 
among women (adjusted odds ratio 17.27, 95% CI 1.57–
189.78; p = 0.02).
To confi rm that associations were not biased by 
assay sensitivity, we conducted a secondary analysis that 
excluded 81 borderline PARV4-negative persons (AU >0.5 
and ODR <1.2) and 35 borderline PARV4-positive persons 
(AU 0.5–2.0, ODR >1.2) (Table 2). The same factors 
as in the main analysis were associated with PARV4 
seropositivity; receipt of intravenous antimalarial drugs 
was not signifi cant in the smaller sample.
Conclusions
We retrospectively analyzed samples obtained during 
a study of elderly Cameroonians from an area where HCV 
infection was hyperendemic and in which we had collected 
much information about potential parenteral modes of 
transmission of blood-borne viruses but less information 
about other routes (10). Because this was a cross-sectional 
study, the time sequence of exposure routes and PARV4 
infection could not be determined. Thus, our results should 
be considered exploratory.
The sensitivity, specifi city, and ability of our assay to 
identify seroconversions are comparable to those of PCR-
based methods for determining active infections and past 
exposure (7–9,13). Exclusion of samples showing low 
antibody levels that might represent nonspecifi c reactivity 
had little effect on the analysis of risk factors.
The results provide some evidence for parenteral 
transmission of PARV4 in the study community. As was 
HCV infection (10), PARV4 infection was associated 
with receipt of intravenous antimalarial therapy. This risk 
factor was found for half of the population we studied, 
whereas intramuscular Depo-Provera and streptomycin 
were administered to few patients. In univariate analysis, 
PARV4 seropositivity was also more common in patients 
treated with oral antituberculosis drugs. Although the 
seroprevalence of PARV4 increased with past exposure 
to intravenous treatments in general, this fi nding was 
not statistically signifi cant because antibodies against 
PARV4 were common among persons who reported no 
such treatments. This fi nding, and the lack of association 
between PARV4 and HCV seropositivity, suggests that 
other, nonparenteral modes of transmission existed.
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Table 1. Prevalence of human parvovirus 4 by patient 
characteristics, Cameroon, 2009* 
Characteristic
No. virus positive/ 
no. tested (%) 
p
value
Age, y  0.04 
 60–64 32/125 (26)  
 65–69 13/96 (14)  
 70–74 17/103 (17)  
 >75 17/127 (13)  
Sex  0.15 
 M 25/178 (14)  
 F 54/273 (20)  
HCV serologic results  0.61 
 Negative 29/178 (16)  
 Positive 47/252 (19)  
Anti-HBcAg  1.00 
 Negative 3/21 (14)  
 Positive 76/430 (18)  
Treponemal antibodies  0.06 
 Absent 28/119 (24)  
 Present 51/332 (15)  
Intravenous treatment for malaria  0.04 
 No 29/216 (13)  
 Yes 50/235 (21)  
Intravenous treatment for other diseases 0.93 
 No 42/239 (18)  
 Yes 37/212 (17)  
No. past intravenous treatments  0.38 
 0 12/88 (14)  
 1–3 33/206 (16)  
 >4 25/116 (22)  
 Unknown 9/41 (22)  
Tuberculosis  0.04 
 No 72/433 (17)  
 Yes, treated with oral drugs only 4/12 (33)  
 Yes, treatment included  
 streptomycin 
3/6 (50)  
Transfusion  0.09 
 No 76/408 (19)  
 Yes 3/43 (7)  
Depo-Provera injections†  0.006
 No 50/268 (19)  
 Yes 4/5 (80)  
Scarifications  0.88 
 No 30/165 (18)  
 Yes 49/286 (17)  
Vaccine scar, left arm  0.005
 Absent 17/53 (32)  
 Present 61/397 (15)  
Vaccine scar, right arm  0.76 
 Absent 27/165 (16)  
 Present 51/284 (18)  
Circumcision (males only)  0.74 
 Medical 9/73 (12)  
 Traditional 16/105 (15)  
*HCV, hepatitis C virus, HBcAg, hepatitis B core antigen.  
†Pharmacia & Upjohn Company, New York, NY, USA. 
PARV4 seropositivity was more common in persons 
60–64 years of age than in older persons. This fi nding has 
3 potential explanations. First, exposure to the virus might 
have fl uctuated over time. Second, titers of antibodies 
against PARV4 might progressively wane, eventually 
leading to false negative results. Third, PARV4 infection 
might increase long-term risk for death, although this 
explanation seems unlikely.
Absence of a vaccine scar on the left arm was associated 
with PARV4 seropositivity. Historical and epidemiologic 
data suggest that in Cameroon, the left side was used for 
smallpox vaccine and the right side for Mycobacterium bovis 
BCG (14,15). Failure of scar development after smallpox 
vaccination might refl ect immunologic characteristics 
associated with greater susceptibility to PARV4 infection.
Our fi ndings suggest that some parenteral transmission 
of PARV4 occurred among elderly Cameroonians, but 
parenteral transmission might not have been the main 
route of infection. The association with past tuberculosis, 
although perhaps coincidental, is intriguing and deserves 
further study.
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Table 2. Correlates of study participants and human parvovirus 4 infection in multivariate analysis, Cameroon, 2009 
Participant characteristic 
All participants After exclusions* 
Adjusted odds ratio (95% CI) p value Adjusted odds ratio (95% CI) p value 
Age group, y      
 60–64 2.21 (1.13–4.31) 0.02  2.88 (1.16–7.17) 0.02 
 65–69 1.01 (0.46–2.24) 0.98  1.20 (0.39–3.70) 0.76 
 70–74 1.16 (0.54–2.46) 0.71  1.51 (0.55–4.16) 0.42 
 >75 1.00   1.00  
Tuberculosis      
 No 1.00   1.00  
 Yes, treated with oral drugs only 2.09 (0.58–7.54) 0.26  2.91 (0.63–13.51) 0.17 
 Yes, treatment included streptomycin 5.21 (0.99–27.37) 0.05  20.96 (1.67–262.99) 0.02 
Vaccine scar, left arm      
 Absent 1.00   1.00  
 Present 0.37 (0.19–0.71) 0.003  0.32 (0.13–0.78) 0.01 
Intravenous treatment for malaria     0.06 
 No 1.00   1.00  
 Yes 1.92 (1.13–3.24) 0.015  1.98 (0.97–4.03) 0.06 
*After exclusion of 81 participants with borderline negative results and 35 with borderline positive results. 
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